GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Epizyme Inc (NAS:EPZM) » Definitions » Net Change in Cash

Epizyme (Epizyme) Net Change in Cash : $-9.10 Mil (TTM As of Jun. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Epizyme Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Epizyme's Net Change in Cash for the three months ended in Jun. 2022 was $-6.36 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2022 was $-9.10 Mil.

Epizyme Net Change in Cash Historical Data

The historical data trend for Epizyme's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epizyme Net Change in Cash Chart

Epizyme Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 148.77 -139.99 53.86 28.73 -69.88

Epizyme Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.45 44.35 -26.18 -20.92 -6.36

Epizyme Net Change in Cash Calculation

Epizyme's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-226.853+125.482+31.492+0
=-69.88

Epizyme's Net Change in Cash for the quarter that ended in Jun. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-54.808+48.71+-0.257+0
=-6.36

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epizyme Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Epizyme's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Epizyme (Epizyme) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Epizyme Inc (NAS:EPZM) » Definitions » Net Change in Cash
Comparable Companies
WVE CLSD PTN LBPH PYXS ENLV VIGL GTBP CRTX VIRX OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
400 Technology Square, 4th Floor, Cambridge, MA, USA, 02139
Website
https://www.epizyme.com
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
Executives
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jerald Korn officer: Chief Operating Officer 128 GORDON RD, NEWTON MA 02468
Joseph Beaulieu officer: Corporate Controller C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Shefali Agarwal officer: Chief Medical Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Royalty Pharma Investments 2019 Icav director, 10 percent owner C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022
Pablo G. Legorreta director 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
Carol Stuckley director C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Roy A Beveridge, director 500 W MAIN ST, LOUISVILLE KY 40202
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Robert B Bazemore director, officer: President & CEO 33 HAYDEN AVE, LEXINGTON MA 02421
Matthew Ros officer: Chief Operating Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Tombesi officer: Chief Financial Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Victoria Vakiener officer: Chief Commercial Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Rp Management, Llc director 110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022